Taysha, UTSW start fund to speed up CNS gene therapies

By The Science Advisory Board staff writers

January 13, 2021 -- Taysha Gene Therapies and the University of Texas Southwestern Medical Center (UTSW) have launched a fund to accelerate the development of adeno-associated virus (AAV) gene therapies for monogenic diseases of the central nervous system (CNS).

Expanding this partnership supports the medical center's discovery efforts to bring about promising therapies while Taysha gets an exclusive option on new programs and intellectual property linked to this deal.

If you like this content, please share it with a colleague!

Related Reading

AllStripes, Taysha Gene Therapies partner on rare disease gene therapy program
AllStripes and Taysha Gene Therapies have entered a multiyear collaboration focused on advancing the development of TSHA-104, an adeno-associated virus...

Taysha nabs rare pediatric disease, orphan drug status
Taysha Gene Therapies has received rare pediatric disease designation and orphan drug designation from the U.S. Food and Drug Administration for TSHA-104,...

Taysha gets $95M in financing to advance gene therapies
Taysha Gene Therapies has closed on $95 million in series B financing to advance gene therapies for monogenic central nervous system diseases.